DEWALT, a leading manufacturer of industrial power tools, hand tools, and accessories, announces the expansion of its initiative to make products in the USA. With this expansion, an additional 60 corded and cordless power tools are being made domestically with global materials. An expansion of production into an existing company-owned plant in Greenfield, Indiana brings the total number of DEWALT plants in the United States to seven, with facilities in Connecticut, Maryland, Kentucky, North Carolina, South Carolina, and Tennessee, making some of the brand’s most popular tools.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7253254-dewalt-expands-made-in-usa-initiative/
https://www.therealtymedics.com - Call (321) 947-7653 to Learn How The Realty Medics can help you avoid nightmare renters & find responsible, easy to work with tenants for your rental property. Being a landlord is hard. Let us help you. We’re Orlando and Central Florida’s Highest 5-Star Rated Property Management Company, according to Google & Yelp Reviews. Engineering Property Management Peace of Mind. Click the link above for a Free Rental Income Estimate.
https://youtu.be/CgfosHjow80
https://www.therealtymedics.com
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Tommy John, the premium men's underwear company, today announced a product line with the NFL's Dallas Cowboys that will see Cowboys branding featured on Tommy John underwear.
As a part of the partnership, Tommy John launched Dallas Cowboys men's underwear that is being sold in the pro shops at AT&T Stadium, the home of the Dallas Cowboys, select Dallas Cowboys Pro Shops, Fans United stores, online at www.tommyjohn.com/cowboys, as well as shop.dallascowboys.com. Tommy John's Cool Cotton and Second Skin Trunks and Boxer Briefs will be emblazoned with the famous Cowboys Star allowing fans to show their support for their favorite team, while being supported by premium underwear. In addition, Tommy John will be exposed to millions of devoted Cowboys fans through Cowboys digital and radio platforms as part of the partnership.
To view the multimedia release go to:
http://www.multivu.com/players/English/7648931-tommy-john-the-big-adjustment/
Since 1984, the National Insurance Crime Bureau (NICB) has published annual reports—known today as Hot Spots—that examine vehicle theft at the national and local level. NICB was originally established in 1912 as the Automobile Protective and Information Bureau and the company focused exclusively on recovering stolen motor vehicles that were insured by its 11 member insurance companies.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70506511-nicb-national-insurance-crime-bureau-annual-vehicle-theft-hot-spots-report/
From the changing nature of work to evolving consumer expectations, executives are facing new challenges as they seek to ensure success in a business climate marked by constant change. CEB (NYSE: CEB) the leading member-based advisory company, today released Top Insights for the World’s Leading Executives to identify the shifts driving change and help organizations embrace the challenges they pose in order to realize meaningful growth in the years ahead.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7291531-ceb-2014-top-insights/
https://www.protectahomeimprovements.co.uk/conservatories/ 01656 743300
Made to Measure Conservatories since 1994 - We are a proud family company business established over 25 years – read About Us so when you call 01656 743300 you know you will be speaking directly to one of our dedicated expert family members.
Conservatories make an excellent addition to any home, whether it is to accommodate guests or an extra living space. Not only do they add value to your property but they also have other benefits that make conservatories suitable for everyone who has the land to utilise.
Bespoke Conservatories Cardiff, Bridgend & Porthcawl - Garage Doors Supplier
We are also a major supplier of all sizes of garage door width and length, singles, doubles triples and bespoke made to measure in a huge array of colours and finishes.
Cepsa Tower, the company's new corporate headquarters that houses almost 2,000 people, is Spain's second tallest building and represents the materialization of Cepsa's growth and internationalization strategy of in recent years, following the entry of International Petroleum Investment Company (IPIC), as sole shareholder.
The headquarters, designed by the architect Norman Foster, reflects the transformation of Cepsa's business model to focus on an increasingly international market. Its height, at 248 metres, provides a unique view of Madrid from its upper floors, taking in some of the city's most emblematic locations such as the Paseo de la Castellana, the Parque del Retiro and the Santiago Bernabéu stadium.
Cepsa today operates an integrated business model spanning the entire hydrocarbon value chain. This integration allows the company to act with greater flexibility and the ability to respond quickly as a business.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7703451-cepsa-new-headquarters-new-company/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Cantor Fitzgerald, a leading financial services firm, today announced that Cantor Fitzgerald, together with its affiliate BGC Partners, Inc., raised approximately $12 million for dozens of charities around the world, at the companies’ annual Charity Day on September 11, 2015. Each year, Cantor Fitzgerald and BGC Partners donate 100% of the global revenues generated on Charity Day to the Cantor Fitzgerald Relief Fund, and to date has raised approximately $125 million globally since its inception.
“We will never forget all of our friends and colleagues who perished on 9/11. Charity Day represents our company’s fundamental commitment to helping others, and allows us to commemorate the events of that day. Giving back is our way of remembering those who lost their lives on 9/11, turning a day of tragedy into a positive and uplifting day for our employees and friends,” said Howard W. Lutnick, Chairman and Chief Executive Officer of Cantor Fitzgerald, L.P. and BGC Partners.
Charity Day is held in commemoration of the 658 Cantor employees and 61 Eurobrokers employees lost in the 9/11 World Trade Center attacks.
To view the multimedia release go to:
http://www.multivu.com/players/English/7620751-cantor-bgc-partners-charity-day-2015/
Nuelle™, a sexual wellness and intimate care company focused on delivering groundbreaking solutions made specifically for women, announces today its Indiegogo campaign to raise awareness and funding for the company’s first product launch Fiera® Arouser for Her™.
In the US, roughly 46% of all American women, aged 18 – 70 have a sexual concern. Among committed couples, intimacy is important for both the health of the relationship and personal wellbeing. Sex, however, is often a tough subject to broach with partners, health care professionals and friends alike. Through its partnership with Indiegogo, Nuelle aims to normalize the conversation about women’s sexual wellbeing and the impact on quality of life, while educating couples about Fiera® Arouser for Her™ and its proven technology to scientifically enhance arousal and desire, naturally.
Co-created with women and healthcare professionals to bring back excitement to connect sexually with her partner, Nuelle’s Fiera® Arouser for Her™ is the first wearable intimacy enhancer used in advance of a sexual experience that is proven to ignite arousal and increase desire among women. In a study (after four weeks of using Fiera), 87% of women said they felt “in the mood” for sex and 83% enjoyed engaging in sex.*
To view the multimedia release go to:
http://www.multivu.com/players/English/7750851-nuelle-indiegogo-fiera-arouser-for-her/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
